Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 2/20 | 0.43 |
| ▸ | FNTB | P49356 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241244 | 0.86 | EGFR (0.47) | KDM4EALDH1A1GAAGLAHTT | |
| SCHEMBL6824403 | 0.85 | KDM4E (0.59) | KDM4EALDH1A1GAAMAPTCASP1 | |
| SCHEMBL6295986 | 0.79 | KDM4E (0.51) | KDM4EALDH1A1GAAGLAHTT | |
| SCHEMBL7411140 | 0.77 | KDM4E (0.71) | PPARGPTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL15332528 | 0.75 | KDM4E (0.46) | PTGS2KDM4EALDH1A1GAAGLA | |
| SCHEMBL4311458 | 0.75 | FNTA (0.44) | ALDH1A1FNTAFNTB | |
| SCHEMBL24074225 | 0.74 | MAP2 (0.55) | KDM4EALDH1A1HTTMAPT | |
| SCHEMBL9017489 | 0.74 | PTGS1 (0.61) | PPARGPTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL3408821 | 0.74 | KDM4E (0.73) | PPARGPTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL4303732 | 0.74 | TSHR (0.52) | PPARGPTGS1PTGS2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| WO-2007061763-A2 | INDOLE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088452-A1 | Indole Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | PPARG 2210/4885PTGS1 1698/4885PTGS2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.